Literature DB >> 15563744

Conclusions: chronic pain studies of lidocaine patch 5% using the Neuropathic Pain Scale.

Charles E Argoff.   

Abstract

Many chronic pain patients have multiple etiologies for their pain, and accurate characterization of pain qualities and pain relief is essential for managing their pain. The ability to utilize a validated tool for assessing pain qualities and for identifying unique analgesic therapy effects on different pain qualities may assist clinicians in devising an appropriate treatment regimen. The Neuropathic Pain Scale (NPS) is a novel pain metric for characterizing pain in 10 dimensions. The ability to differentiate among pain qualities for each patient may result in a more refined and effective choice of therapy. The three research articles in this Supplement demonstrate the utility of the NPS in chronic pain patients treated with the lidocaine patch 5%, a peripherally acting medication that is not associated with systemic accumulation of the active drug. Significant reduction in the intensity of commonly reported pain qualities in patients with neuropathic and non-neuropathic chronic pain due to low-back pain, osteoarthritis, post-herpetic neuralgia, and painful diabetic neuropathy were achieved. The NPS offers clinicians a reliable means to accurately identify pain qualities associated with each individual patient and to target and assess the efficacy of various therapeutic options on those pain components. Utilizing the NPS, the lidocaine patch 5% was effective in treating chronic pain of both neuropathic and non-neuropathic origins suggesting that a given treatment's effect on various pain qualities may be consistent across pain types.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15563744     DOI: 10.1185/030079904X12979

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  4 in total

1.  Ongoing pain in the MIA model of osteoarthritis.

Authors:  Ping Liu; Alec Okun; Jiyang Ren; Rui-chen Guo; Michael H Ossipov; Jennifer Xie; Tamara King; Frank Porreca
Journal:  Neurosci Lett       Date:  2011-01-15       Impact factor: 3.046

2.  Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB).

Authors:  Andrea L Cheville; Jeff A Sloan; Donald W Northfelt; Anand P Jillella; Gilbert Y Wong; James D Bearden Iii; Heshan Liu; Paul L Schaefer; Benjamin T Marchello; Bradley J Christensen; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2009-01-13       Impact factor: 3.603

3.  Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis.

Authors:  Mark Ritchie; Hiltrud Liedgens; Mark Nuijten
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

4.  Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial.

Authors:  Andreas Binder; Jean Bruxelle; Peter Rogers; Guy Hans; Irmgard Bösl; Ralf Baron
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.